Turn Therapeutics (NASDAQ:TTRX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Turn Therapeutics (NASDAQ:TTRX) to a hold rating in a research note issued to investors on Saturday.

A number of other analysts have also recently commented on the company. D. Boral Capital restated a “buy” rating and issued a $8.00 price target on shares of Turn Therapeutics in a research report on Tuesday, March 24th. Weiss Ratings raised Turn Therapeutics from a “sell (e)” rating to a “sell (d-)” rating in a research report on Monday, July 13th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $8.00.

Turn Therapeutics Trading Up 10.2%

Turn Therapeutics stock opened at $10.05 on Friday. Turn Therapeutics has a 52-week low of $2.57 and a 52-week high of $26.50. The company has a market cap of $299.39 million and a P/E ratio of -52.89. The company has a quick ratio of 2.23, a current ratio of 2.23 and a debt-to-equity ratio of 0.97. The business has a 50-day simple moving average of $6.47 and a two-hundred day simple moving average of $4.73.

Turn Therapeutics (NASDAQ:TTRX) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.03) earnings per share for the quarter.

Institutional Investors Weigh In On Turn Therapeutics

Institutional investors have recently bought and sold shares of the business. Hodges Capital Management Inc. purchased a new position in shares of Turn Therapeutics in the fourth quarter valued at about $39,000. LPL Financial LLC bought a new position in shares of Turn Therapeutics in the fourth quarter worth about $51,000. Tamar Securities LLC purchased a new stake in shares of Turn Therapeutics during the fourth quarter worth about $59,000. Composition Wealth LLC bought a new stake in Turn Therapeutics during the 4th quarter valued at approximately $63,000. Finally, Geode Capital Management LLC bought a new stake in Turn Therapeutics during the 4th quarter valued at approximately $68,000.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.